Search results for "Stomach Neoplasm"

showing 10 items of 188 documents

Malignant Rhabdoid Tumor in the Gastric Wall of an Aged Orangutan (Pongo pygmaeus)

1994

A 34-year-old female orangutan ( Pongo pygmaeus) developed renal failure and became uremic. At necropsy, large gastric masses were present around the cardia and in the corpus. Abdominal metastases occurred in the liver, pancreas, and right ovary. Light microscopic examination of the tumor revealed polygonal cells with vesicular nuclei and prominent nucleoli. The growth pattern was predominantly solid. Focal areas contained excentric cytoplasmic intermediate filament inclusions, as identified by immunohistochemistry and electron microscopy. Immunohisiochemical procedures demonstrated mainly the vimentin type of intermediate filaments. Except for occasional cytokeratin, other intermediate fil…

0301 basic medicinePathologymedicine.medical_specialty040301 veterinary sciencesVimentinHistogenesisBiologyMalignancy0403 veterinary science03 medical and health sciencesCytokeratinPongo pygmaeusStomach NeoplasmsPongo pygmaeusmedicineAnimalsVimentinIntermediate filamentRhabdoid TumorHistiocyteGeneral Veterinary04 agricultural and veterinary sciencesAnatomymedicine.diseaseApe DiseasesMicroscopy Electron030104 developmental biologybiology.proteinImmunohistochemistryFemaleVeterinary Pathology
researchProduct

Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer

2018

Although many anticancer agents for gastric cancer have been developed, the prognosis for many patients remains poor. Recently, costimulatory immune molecules that reactivate antitumor immune responses by utilizing the host immune system have attracted attention as new therapeutic strategies. CD137 is a costimulatory molecule that reportedly potentiates the antitumor activity of tumor-targeting monoclonal antibodies (mAbs) by enhancing antibody-dependent cellular cytotoxicity. However, it remains unclear whether CD137 stimulates tumor-regulatory activity in gastric cancer. In this study, we investigated the antitumor effects of CD137 stimulation on gastric cancer cells administered tumor-ta…

0301 basic medicinePhysiologyCytotoxicityCancer Treatmentlcsh:MedicineNK cellsToxicologyPathology and Laboratory MedicineAntineoplastic Agents ImmunologicalSpectrum Analysis Techniques0302 clinical medicineImmune PhysiologyCellular typeslcsh:ScienceInnate Immune SystemCytotoxicity AssayMultidisciplinarybiologyChemistryImmune cellsCD137Drug SynergismFlow CytometryRecombinant ProteinsUp-RegulationGene Expression Regulation NeoplasticKiller Cells NaturalOncologySpectrophotometry030220 oncology & carcinogenesisCytokinesWhite blood cellsFemaleTumor necrosis factor alphaCytophotometryAntibodyResearch ArticleCell biologyBlood cellsCell Survivalmedicine.drug_classImmunologyAntibodies Monoclonal HumanizedResearch and Analysis MethodsMonoclonal antibody03 medical and health sciencesImmune systemStomach NeoplasmsCell Line TumorGastrointestinal TumorsmedicineHumansSecretionCell ProliferationMedicine and health sciencesBiology and life scienceslcsh:RCancers and NeoplasmsCancerTrastuzumabMolecular Developmentmedicine.diseaseGranzyme BGastric Cancer4-1BB Ligand030104 developmental biologyAnimal cellsImmune SystemCancer cellCancer researchbiology.proteinlcsh:QPhysiological ProcessesDevelopmental BiologyPLOS ONE
researchProduct

Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas

2020

Background Gastroesophageal adenocarcinomas (GEAs) are heterogeneous cancers where immune checkpoint inhibitors have robust efficacy in heavily inflamed microsatellite instability (MSI) or Epstein-Barr virus (EBV)-positive subtypes. Immune checkpoint inhibitor responses are markedly lower in diffuse/genome stable (GS) and chromosomal instable (CIN) GEAs. In contrast to EBV and MSI subtypes, the tumor microenvironment of CIN and GS GEAs have not been fully characterized to date, which limits our ability to improve immunotherapeutic strategies. Patients and methods Here we aimed to identify tumor-immune cell association across GEA subclasses using data from The Cancer Genome Atlas (N = 453 GE…

0301 basic medicineT cellmedicine.medical_treatmentAdenocarcinomaArticle03 medical and health sciences0302 clinical medicineImmune systemStomach NeoplasmsTumor MicroenvironmentMedicineHumansTumor microenvironmentbusiness.industryMicrosatellite instabilityHematologyImmunotherapyCell cyclemedicine.diseaseImmunohistochemistry030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchAdenocarcinomaMicrosatellite InstabilitybusinessCD8
researchProduct

Early detection of gastric cancer beyond endoscopy - new methods

2021

Early detection of gastric cancer is remaining a challenge. This review summarizes current knowledge on non-invasive methods that could be used for the purpose. The role of traditional cancer markers such as CEA, CA 72-4, CA 19-9, CA 15-3, and CA 12-5 lies mainly in therapy monitoring than early detection. Most extensive studied biomarkers (pepsinogens, ABC method) are aiming at the detection of precancerous lesions with modest sensitivity for cancer. Tests based on the detection of cancer-specific methylation patterns (PanSeer), circulating proteins and mutations in circulating tumour DNA (CancerSEEK), as well as miRNA panels have demonstrated promising results bringing those closer to pra…

0301 basic medicinemedicine.diagnostic_testbusiness.industryGastroenterologyEarly detectionCancerEndoscopymedicine.diseaseSurvival AnalysisExtracellular vesiclesEndoscopy03 medical and health sciences030104 developmental biology0302 clinical medicineStomach Neoplasms030220 oncology & carcinogenesismicroRNACancer researchHumansMedicineTherapy monitoringbusinessEarly Detection of CancerBest Practice & Research Clinical Gastroenterology
researchProduct

Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?

2021

Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic and mechanistic biology into advanced GEPNEN management is limited. ‘Targeted’ treatments such as somatostatin analogues, peptide receptor radiotherapy, tyrosine kinase inhibitors and mammalian target…

0301 basic medicinemedicine.medical_treatmentcancer geneticsNeuroendocrine tumorsBioinformaticschemotherapyMolecular oncologyEpigenesis Genetic03 medical and health sciences0302 clinical medicinemolecular oncologyStomach NeoplasmsIntestinal NeoplasmsBiomarkers TumormedicineHumanscancer genetics; chemotherapy; immunotherapy; molecular oncology; neuroendocrine tumorsEpigeneticsPrecision Medicine610 Medicine & healthbusiness.industryGastroenterologyImmunotherapymedicine.diseasePancreatic NeoplasmsRadiation therapyClinical trial030104 developmental biologyTargeted drug delivery030220 oncology & carcinogenesis570 Life sciences; biologyIdentification (biology)immunotherapyneuroendocrine tumorsbusiness
researchProduct

Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.

2006

Gastric adenomas are rare neoplastic growths characterized by localized polypoid proliferations of dysplastic epithelium that tend to progress to infiltrating adenocarcinoma. Therefore, the identification of molecular markers that could reliably recognize adenomas at risk of progression is advocated in the clinical management. In this study we investigated, in a series of gastric adenoma specimens from an area at high risk of gastric cancer, the relationship between clinicopathological characteristics of adenoma and Helicobacter pylori infection, APC mutational status, and COX-2 and the down-stream enzyme mPGES1 expression. Helicobacter pylori infection, detected in 24%, and 33% by histolog…

AdenomaMaleGenes APCAdenomaAdenocarcinomamedicine.disease_causegastric adenomaHelicobacter InfectionsHelicobacter pyloryStomach NeoplasmsmedicineHumansAPC mutationsAgedProstaglandin-E SynthasesAged 80 and overMutationbiologyHelicobacter pyloribusiness.industryCancerAPC mutations; COX-2; gastric adenoma; Helicobacter pyloriHistologyHematologyHelicobacter pyloriCOX-2Middle Agedmedicine.diseasebiology.organism_classificationdigestive system diseasesEpitheliumIntramolecular Oxidoreductasesmedicine.anatomical_structureOncologyDysplasiacyclooxygenase-2Cyclooxygenase 2Gastric MucosaMutationCancer researchAPC-mutations gastric adenoma Helycobacter pyloriAdenocarcinomaFemalebusiness
researchProduct

Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer.

1999

The expression and prognostic role of cyclin D1, cyclin E, and p21 (WAF1/CIP1) were immunohistochemically investigated in 413 curatively resected gastric carcinomas. p21 was expressed in 65.4 per cent (n=270), cyclin D1 in 23.7 per cent (n=98), and cyclin E in 13.6 per cent ( n=56) of the tumours. The expression of p21, cyclin D1, and cyclin E was positively associated with the papillary or tubular type of the WHO classification, as well as with the intestinal type according to the Lauren classification. No significant correlation could be found between the expression of p21, cyclin D1 and cyclin E and the parameters pT category, lymph node involvement, and blood vessel and lymphatic vessel…

AdultCyclin-Dependent Kinase Inhibitor p21MaleCyclin ECyclin DCyclin BBiologyPathology and Forensic MedicineImmunoenzyme TechniquesCyclin D1Stomach NeoplasmsCyclinsCyclin EmedicineBiomarkers TumorHumansCyclin D1Lymph nodeCyclinAgedAged 80 and overCancerCell cycleMiddle Agedmedicine.diseasePrognosisNeoplasm ProteinsSurvival Ratemedicine.anatomical_structureGastric Mucosabiology.proteinCancer researchFemaleFollow-Up StudiesThe Journal of pathology
researchProduct

Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence…

2011

Abstract Background Several polymorphisms of genes involved in the immunological recognition of Helicobacter pylori and regulating apoptosis and proliferation have been linked to gastric carcinogenesis, however reported data are partially conflicting. The aim of our study was to evaluate potential associations between the presence of gastric cancer (GC) and high risk atrophic gastritis (HRAG) and polymorphisms of genes encoding Angiotensin converting enzyme (ACE), Nod-like receptor 1 (NOD1), Toll-like receptor 4 (TLR4) and FAS/FASL. Methods Gene polymorphisms were analyzed in 574 subjects (GC: n = 114; HRAG: n = 222, controls: n = 238) of Caucasian origin. ACE I/D (rs4646994), NOD1 796G>…

AdultGastritis AtrophicMaleFas Ligand ProteinGenotypeAtrophic gastritisPeptidyl-Dipeptidase AWhite PeopleFas ligandHelicobacter InfectionsRisk FactorsStomach NeoplasmsNod1 Signaling Adaptor ProteinNOD1GenotypemedicineGeneticsHumansGenetics(clinical)fas ReceptorAllelesGenetics (clinical)AgedAged 80 and overPolymorphism GeneticHelicobacter pyloribiologyCancerAngiotensin-converting enzymeMiddle AgedHelicobacter pylorimedicine.diseasebiology.organism_classificationToll-Like Receptor 4ApoptosisImmunologybiology.proteinFemalePrecancerous ConditionsResearch ArticleBMC Medical Genetics
researchProduct

Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia.

2012

Helicobacter pylori infection and atrophic gastritis are related to an increased risk for gastric cancer. There is a decrease in global H. pylori prevalence. We analyzed the prevalence of H. pylori infection in Latvia by the plasma IgG test and the presence of atrophy by means of pepsinogen testing.This subanalysis was carried out on a randomly selected cross-sectional sample of a general population of adults to access cardiovascular risk factors. Plasma samples were screened for H. pylori IgG (cutoff value 24 U/ml), and pepsinogens (Pg) I and II. Pg cutoff values of PgI/PgII ≤ 3 and PgI ≤ 70 ng/ml were used to assess the prevalence of atrophy of any grade and PgI/PgII ≤ 2 and PgI ≤ 30 ng/m…

AdultGastritis AtrophicMalemedicine.medical_specialtyHelicobacter pylori infectionAdolescentCross-sectional studyAtrophic gastritisGastroenterologySeverity of Illness IndexHelicobacter InfectionsYoung AdultAtrophySex FactorsPredictive Value of TestsRisk FactorsStomach NeoplasmsInternal medicinePepsinogen AmedicinePepsinogen CPrevalenceHumansYoung adultAgedAged 80 and overChi-Square DistributionHepatologybiologyHelicobacter pyloribusiness.industryGastroenterologyAge FactorsCancerMiddle Agedbacterial infections and mycosesmedicine.diseaseAntibodies BacterialLatviaCross-Sectional Studiesbiology.proteinLinear ModelsFemaleGastritismedicine.symptomAntibodybusinessPrecancerous ConditionsBiomarkersEuropean journal of gastroenterologyhepatology
researchProduct

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

2018

Background:Gastric cancer is common malignancy and exhibits a poor prognosis. At the time of diagnosis, the majority of patients present with metastatic disease which precludes curative treatment. Non-invasive biomarkers which discriminate early from advanced stages or predict the response to treatment are urgently required. This study explored the cytokeratin-18 fragment M30 and full-length cytokeratin-18 M65 in predicting treatment response and survival in a randomized, placebo-controlled trial of advanced gastric cancer.Methods:Patients enrolled in the SUN-CASE study received sunitinib or placebo as an adjunct to standard therapy with leucovorin (Ca-folinate), 5-fluorouracil, and irinote…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyIndolesmedicine.medical_treatmentLeucovorinAntineoplastic AgentsPlaceboDisease-Free SurvivalMetastasislaw.inventionPlacebos03 medical and health sciences0302 clinical medicineRandomized controlled trialStomach NeoplasmslawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorSunitinibHumansMedicinePyrrolesProgression-free survivalRC254-282AgedAged 80 and overChemotherapyKeratin-18business.industrySunitinibCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMiddle Agedmedicine.diseasePeptide FragmentsIrinotecan030104 developmental biology030220 oncology & carcinogenesisCamptothecinFemaleFluorouracilbusinessmedicine.drugTumor Biology
researchProduct